Simvastatin Caritid Atherosclerosis HS-CRP And Cerebrovascular Correlation Of Clinical Events

ObjectiveIschemic cerebrovascular disease is the basic cause of atherosclerosis(AS).Clinicalevents leading to cerebral blood vessels is mainly due to atherosclerotic plaque rupture andthrombosis.The plaque rupture depends on plaque vulnerability,and with peripheral bloodlevels of hs-CRP are closely related. As plaque dyslipidemia are important risk factors thataffect plaque stability is the external factors that could lead to hardening stress-inducedblood vessel inflammation and hemodynamic abnormalities. While simvastatin canregulate blood fat, whether to improve endothelial function and reduce hs-CRP levels,stability and reverse the plaque, thereby reducing the occurrence of cerebrovascular events.The issue on carotid atherosclerosis were treated with simvastatin treatment, to study themorphology of carotid artery ultrasound before and after treatment and changes inultrasonic echo characteristics, and hs-CRP levels in peripheral blood, and to exploreSimvastatin carotid atherosclerosis, hs-CRP and the effect on cerebrovascular clinicalevents. And with peripheral blood levels of hs-CRP are closely related.MethodsOut-patient health check on carotid artery ultrasound confirmed carotidatherosclerosis in patients, while testing the peripheral blood of hs-CRP levels and wererandomly divided into two groups. Control group: treatment and improve the food onlyway of life; treatment group: In addition to the above, plus simvastatin 20 mg / d, the twogroups in the control of blood pressure, blood glucose control, smoking cessation,antiplatelet therapy, and so consistent. Six months after treatment, carotid artery ultrasoundand review of peripheral blood levels of hs-CRP were observed before and after treatment,and treatment of carotid artery intima between the two groups in membrane(CIMT),plaque vulnerability, ultrasound characteristics, hs-CRP level changes, and compare thetwo groups were followed up for six months in place the risk of cerebrovascular clinicalevents.ResultsThe control group before and after treatment CIMT, the number of vulnerable plaques,hs-CRP levels were not significantly reduce P> 0.05; treatment group before and aftertreatment were significantly lower P <0.05; treatment between the two groups P <0.05; theend of treatment is two groups of cerebral vascular clinical events compared P <0.05.ConclusionsAs a lipid-lowering drug simvastatin not only regulate lipid and also reduce hs-CRPlevels, reduce the number of vulnerable plaque, stability and reverse the plaque, and lowercarotid atherosclerotic plaques in patients with ischemic cerebrovascular disease risk ofclinical events, for the prevention of ischemic stroke to provide the theoretical basis andinterventions.